Risk of Hepatic Encephalopathy in Obstructive Jaundice

Pathophysiology and Risk Factors

Obstructive jaundice does not typically cause hepatic encephalopathy unless there are complications or advanced liver disease, as hepatic encephalopathy primarily occurs in the setting of cirrhosis with portal hypertension or significant portosystemic shunting 1, 2
Hepatic encephalopathy (HE) occurs primarily in patients with cirrhosis or portosystemic shunts, not typically in isolated obstructive jaundice 3
The risk of HE increases if obstructive jaundice leads to secondary biliary cirrhosis with portal hypertension development 4
The development of portosystemic shunts increases the risk of HE 2, 3

In patients with obstructive jaundice who develop HE, the presentation ranges from subtle cognitive changes (covert HE) to more obvious neurological dysfunction (overt HE) 3
Covert HE affects 30-70% of patients with cirrhosis and is associated with reduced quality of life, impaired socio-economic potential, and increased risk of developing overt HE 3, 5
The Animal Naming Test is recommended as a bedside screening tool for HE 3, 5
Blood ammonia levels should be measured but are not diagnostic alone 6

Treatment should focus on addressing the underlying obstructive cause while managing any HE symptoms 1, 2
Non-absorbable disaccharides (lactulose) are first-line treatment for both acute overt HE and prevention 2, 7
Rifaximin (550 mg twice daily) should be added to lactulose for prevention of recurrent episodes after a second episode 7
Identify and treat precipitating factors, which is crucial as nearly 90% of patients improve with correction of precipitating factors alone 8

Patients with obstructive jaundice undergoing TIPS have increased risk of developing HE 2, 7
Routine prophylactic therapy with lactulose or rifaximin is not recommended for post-TIPS HE prevention 7
Patients with covert HE should be treated with non-absorbable disaccharides to prevent progression to overt HE 3, 5

After resolution of obstructive jaundice, patients should be monitored for neurological manifestations to adjust treatment, signs of recurring HE, and risk of falls due to potential gait and walking impairment 4

Liver transplantation leads to significant improvement in most cognitive functions in patients with HE, with improvements beginning around 6 months post-transplant 6
The presence of HE in patients with equivalent MELD scores significantly increases short and medium-term risk of death by 2-4 times compared to patients without HE 6